CALGB-30610; Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide
Investigation of Radiation Therapy Regimens for Small Cell Lung Cancer
Brief description of study.
Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as etoposide and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known which radiation therapy regimen is more effective when given together with chemotherapy in treating patients with limited-stage small cell lung cancer. This randomized phase III trial is comparing different chest radiation therapy regimens to see how well they work in treating patients with limited-stage small cell lung cancer.
Detailed description of study
The purpose of this study is to determine whether administering high-dose thoracic radiotherapy, 70 Gy (2 Gy once daily over 7 weeks) or 61.2 Gy (1.8 Gy once daily for 16 days followed by 1.8 Gy twice daily for 9 days), will improve median and 2-year survival compared with 45 Gy (1.5 Gy twice daily over 3 weeks) in patients with limited-stage small cell lung cancer.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Lung Cancer
-
Age: 18 years - 100 years
-
Gender: All
This study investigates the effectiveness of different chest radiation therapy regimens when combined with chemotherapy for treating patients with limited-stage small cell lung cancer. Radiation therapy uses high-energy x-rays to kill tumor cells, while chemotherapy drugs like etoposide and cisplatin stop tumor cells from growing by killing them or stopping them from dividing.
Participants in this trial will receive one of the following radiation therapy regimens: 70 Gy over 7 weeks, 61.2 Gy with a combination of daily and twice-daily doses, or 45 Gy given twice daily for 3 weeks. The study aims to determine which regimen improves median and 2-year survival rates for patients.
- Who can participate: Participants aged 18 years and older with limited-stage small cell lung cancer are eligible for this study. Key eligibility factors include prior treatment history and overall health status.
- Study details: Participants will receive one of three different radiation therapy regimens along with chemotherapy. The study will compare these regimens to see which one improves survival rates.
